Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A

SSZSE:301093
43.74
CNY
-0.61
(-1.38%)
0.18EPS
334.03P/E
13.45BMarket Cap
Apr 26Next Earn

Total Valuation

CNY

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A carries a market capitalization of 13.45B, placing it among publicly traded companies globally. Its enterprise value stands at 12.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap13.45B
Enterprise Value12.51B

Important Dates

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A's next confirmed earnings release is scheduled for April 26, 2027.

Earnings Date4/26/2027

Share Statistics

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A has 213.13M shares outstanding.

Shares Outstanding213.13M

Valuation Ratios

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 334.03. The price-to-sales ratio is 20.44, and the price-to-book ratio stands at 6.10.

PE Ratio334.03
PS Ratio20.44
PB Ratio6.10
P/TBV Ratio6.33

Enterprise Valuation

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A trades at an EV/EBITDA multiple of 283.10 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 19.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 283.10 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.51B versus a market cap of 13.45B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales19.59
EV / EBITDA283.10
EV / EBIT283.10

Financial Position

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A maintains a current ratio of 5.32, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.94, indicating elevated leverage, while an interest coverage ratio of 16.89 demonstrates strong ability to service its debt obligations.

Current Ratio5.32
Quick Ratio3.68
Debt / Equity5.94
Debt / EBITDA2.97
Interest Coverage16.89

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 675,567.02 in revenue per employee across its workforce of 945.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee675,567.02
Employee Count945.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A recorded 4.43M in income tax expense. That works out to an effective tax rate of 10.45, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 42.43M, leaving 39.07M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax4.43M
Effective Tax Rate10.45

Stock Price Statistics

CNY

As of the close on November 17, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A's stock has gained approximately 17.95% over the past 52 weeks. The 50-day moving average sits at 56.28, while the 200-day moving average is 69.53.

52-Week Price Change17.95%
50-Day Moving Average56.28
200-Day Moving Average69.53

Income Statement

CNY

Over the twelve months ended September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A generated 638.41M in revenue and converted that into 39.07M in net income, yielding earnings per share of 0.18. EBITDA reached 44.18M, while operating income came in at 42.91M.

Revenue638.41M
Gross Profit260.19M
Operating Income42.91M
Pretax Income42.43M
Net Income39.07M
EBITDA44.18M
EBIT44.18M
Earnings Per Share (EPS)0.18

Balance Sheet

CNY

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A holds 1.08B in cash and equivalents against 131.14M in total debt, resulting in a net debt position of -121.24M. Total book value stands at 2.21B, with working capital of 1.26B providing operational flexibility.

Cash & Cash Equivalents1.08B
Total Debt131.14M
Net Debt-121.24M
Equity (Book Value)2.21B
Book Value Per Share10.35
Working Capital1.26B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-98.79M

Margins

Over the twelve months ended September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A posted a gross margin of 40.76, reflecting its pricing power and cost economics. The operating margin of 6.72 and net profit margin of 6.12 provide insight into operational efficiency.

Gross Margin40.76
Operating Margin6.72
Pretax Margin6.65
Profit Margin6.12
EBITDA Margin6.92

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A paid dividends of 0.05 per share. The dividend payout ratio of 28.58 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A shareholders.

Dividend Per Share0.05
Payout Ratio28.58
Shareholder Yield0.05

Stock Splits

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A's most recent stock split took place on July 16, 2026 with a 10:13 split ratio.

Last Split Date7/16/2026
Split Ratio10:13

Scores

As of September 30, 2026, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A has an Altman Z-Score of 19.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score19.69